counter hit make

CNBC Daily Open: GameStop can't stop, Dow drops

CNBC Daily Open: GameStop can't stop, Dow drops
0 46

A screen displays the logo and trading information for GameStop on the floor of the New York Stock Exchange.

Brendan McDermid | Reuters

This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here.

What you need to know today

Weak data dents Dow
The Dow Jones Industrial Average dropped more than 100 points after weak manufacturing data raised concerns about the strength of the U.S. economy. However, the S&P 500 edged higher by 0.11%, while the Nasdaq Composite gained 0.56%. Nvidia jumped almost 5% after introducing new artificial intelligence chips. The yield on the 10-year Treasury fell on weaker-than-expected ISM manufacturing data, which came in at 48.7 in May. A reading below 50 is indicative of a contraction. Oil prices fell more than 3% as OPEC+ plans to phase out voluntary production cuts. 

India stocks sink as election vote counting starts
India’s Nifty and BSE Sensex fell sharply as the world’s most populous country began counting votes, with early leads showing a closer than expected race. Both indexes shot to record highs on Monday after Prime Minister Narendra Modi was projected to win a rare third term by exit polls over the weekend. Elsewhere, South Korea’s Kospi, Japan’s Nikkei 225, Australia’s S&P/ASX 200 were all trading lower. Hong Kong’s Hang Seng inched higher and Mainland China’s CSI 300 index rose 0.39%.

GameStop can’t stop
Shares of GameStop closed 21% higher after jumping more than 70%, as meme stock leader Keith Gill appeared to hold on to a massive position in the video game retailer. The Wall Street Journal reported that E-Trade was considering banning Gill from its platform over concerns of potential market manipulation. Gill, who goes by “DeepF—–Value” on Reddit and “Roaring Kitty” on YouTube and X, posted a screenshot of his portfolio on Monday, showing the value of his common stock alone jumped to $140 million from $115.7 million as of Friday’s close. The post could not be independently verified by CNBC.

Skin cancer vaccine
Moderna and Merck reported that their experimental vaccine, administered to patients with the deadliest form of skin cancer in conjunction with the therapy Keytruda, demonstrated improved survival rates and durable efficacy. Nearly 75% of patients who received the combination were alive and cancer-free at the 2.5-year mark, compared to 55.6% of patients who received Keytruda alone.

Microsoft, Alphabet layoffs
Microsoft will cut some jobs at its mixed reality division, affecting the department that helps make HoloLens. This move reflects a shift in Microsoft’s focus towards AI technologies. Alphabet is also laying off at least 100 employees from its cloud unit, one of its fastest growing businesses, CNBC has learned.

[PRO] ‘Missed’ AI stock
Investors have “completely missed’ this critical artificial intelligence chip stock, says Liontrust fund manager Clare Pleydell-Bouverie. The stock is up more than 5% this year and 25% over the last 12 months, which is modest compared to some fated AI players. 

The bottom line

Wall Street had a strong May, despite some late jitters. The Nasdaq Composite reached a new high, breaching 17,000 for the first time, and ended up 6.9% for the month — its best performance since November 2023.

Much of this success was fueled by Nvidia’s post-earnings surge. The artificial intelligence giant soared 27% in May. On the first trading day of June, it gained nearly 5% after announcing plans to launch a new AI chip, just months after its last release, signaling a bold move against competitors.

In another area of growth, the weight-loss market is projected to be worth $100 billion by the end of the decade. While Eli Lilly and Novo Nordisk offerings have been the primary focus, their dominance isn’t guaranteed as new competitors emerge. For those averse to needles, drug makers are developing weight-loss pills.

Structure Therapeutics released data from a clinical trial showing a 6% weight loss after patients took its GSBR-1290 pill for 12 weeks, challenging an experimental pill from Eli Lilly. Structure Therapeutics’ shares jumped over 50% following the news. According to CNBC’s Pia Singh, JP Morgan anticipates even higher gains for the company.

Concerns about the strength of the economy weighed on the Dow. The Atlanta Federal Reserve’s GDPNow tracker, which monitors economic growth, sharply lowered its second-quarter growth forecast to 1.8% from 2.7%, following disappointing news from the manufacturing sector.

Katerina Simonetti, senior VP and private wealth advisor at Morgan Stanley Private Wealth Management, told CNBC that markets are “trading sideways” as they try to assess valuations.  

“We’re in a higher interest rate environment, which is of course effecting the consumer and as we see rising credit card debt,” Simonetti said. “The Fed is most likely to wait for the CPI number to get closer to their [2%] target data before they are going to move rates, which means it is going to affect the consumer behaviour and corporate earnings.

“We are early in the month of June, its only natural that the market is trading sideways a bit as we’re figuring out valuations. And it will be like this until we get into the next earning season,” Simonetti warned. 

CNBC’s Jeff Cox, Yun Li, Pia Singh, Brian Evans, Jesse Pound, Alex Harring, Spencer Kimball, Annika Kim Constantino, Christina Cheddar Berk, Sophie Kiderlin, Jorden Novet, Lillian Rizzo, Jennifer Elias, Shreyashi Sanyal and Alex Sherman contributed to this report.

Leave A Reply

Your email address will not be published.